Cinobufagin induced myocardial cell toxicity in H9c2 cells via inhibiting histone methyltransferase SMYD1 expression
Huimin Wu(Huazhong University of Science and Technology), Liang Zhang(The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture), Langqun Chen(Nanjing University of Chinese Medicine), Yujie Xiang(Nanjing University of Chinese Medicine), Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Zhang(Innovacell Biotechnologie (Austria)), Jing Ye(East China University of Science and Technology), Hong Zhang(Ocean University of China), Ying Wang(Hebei Medical University), Jiahe Wang(Second Military Medical University), Siyu Cheng(Nanjing University of Chinese Medicine), Jiahui Ying(Nanjing University of Chinese Medicine), Yiran Cheng(Sichuan Agricultural University)
Cited by 0
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.8k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k